Clinical trial
An Open Label Phase 2a Ascending Multiple Dose Safety, Efficacy, and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Adolescents and Adults With Sickle Cell Disease.
NCT06144749 is registered in ClinicalTrials.gov with Hillhurst Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Phase 2a Ascending Multiple Dose Safety, Efficacy, and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Adolescents and Adults With Sickle Cell Disease.
- Lead sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 15, 2025
- Completion date
- June 30, 2026
- Enrollment
- 13 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.